Exploring the Full Potential of Risk-Sharing Agreements Between Pharma Companies and Payors
Health systems, health insurance companies, and other payors around the world are trying to strike the right balance between containing costs and giving patients access to innovative therapies. In doing so, they are putting the traditional pharmaceutical pricing model under intense pressure. Overall health care cost inflation, increasing market-access restrictions, and the growing use of cost-effectiveness assessments make it highly likely that the use of risk-sharing agreements will rise. Pharmaceutical companies that take an integrated approach to risk sharing can design deals that create benefits for themselves and payors.
You may also be interested in...
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.